Elena Kornetova

Dr. Elena Kornetova

Tomsk National Research Medical Center, Tomsk, Tomskaya Oblast’, Russia
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
AHA.F.Y. Al Hadithy
A.F.Y. Al Hadithy
SISvetlana Ivanova
Svetlana Ivanova
PPP. Pechlivanoglou
P. Pechlivanoglou
ASArkadiy Semke
Arkadiy Semke
OFO. Fedorenko
O. Fedorenko
ALA.J.M. Loonen
A.J.M. Loonen

30 June 2021 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
LSLiudmila Smirnova
Liudmila Smirnova
VYVasily L. Yarnykh
Vasily L. Yarnykh
DKDaria A. Kamaeva
Daria A. Kamaeva
EKElena Kornetova
Elena Kornetova
ASArkadiy Semke
Arkadiy Semke
SISvetlana Ivanova
Svetlana Ivanova
Myelin deficiency is commonly recognized as an important pathological feature of brain tissues in schizophrenia (SZ). In this pilot study, global myelin content abnormalities in white matter (WM) and gray matter (GM) of SZ patients were non-invasively investigated using a novel clinically-targeted quantitative myelin imaging technique, fast macromolecular proton fraction (MPF) mapping. MPF maps were obtained from 23 healthy subjects and 31 SZ patients using a clinical 1.5T magnetic resonance imaging (MRI) scanner. Mean MPF in WM and GM was compared between the healthy control subjects and SZ patients with positive and negative leading symptoms using the multivariate analysis of covariance. The SZ patients had significantly reduced MPF in GM (p < 0.001) and WM (p = 0.02) with the corresponding relative decrease of 5% and 3%, respectively. The effect sizes for the myelin content loss in SZ relative to the control group were 1.0 and 1.5 for WM and GM, respectively. The SZ patients with leading negative symptoms had significantly lower MPF in GM (p < 0.001) and WM (p = 0.003) as compared to the controls and showed a significant MPF decrease in WM (p = 0.03) relative to the patients with leading positive symptoms. MPF in WM significantly negatively correlated with the disease duration in SZ patients (Pearson’s r = −0.51; p = 0.004). This study demonstrates that chronic SZ is characterized by global microscopic brain hypomyelination of both WM and GM, which is associated with the disease duration and negative symptoms. Myelin deficiency in SZ can be detected and quantified by the fast MPF mapping method.

11 July 2019 in BMC Genomics
Verified
Journal Article
Open access
PDF file
LSLiudmila Smirnova
Liudmila Smirnova
ASAlexandr Seregin
Alexandr Seregin
IBIrina Boksha
Irina Boksha
EDElena Mihaqlovna Dmitrieva
Elena Mihaqlovna Dmitrieva
GSGerman Simutkin
German Simutkin
VZVictor Zgoda
Victor Zgoda
Purpose of study is revealing significant differences in serum proteomes in schizophrenia and bipolar disorder (BD). Quantitative mass-spectrometry based proteomic analysis was used to quantify proteins in the blood serum samples after the depletion of six major blood proteins. Comparison of proteome profiles of different groups revealed 27 proteins being specific for schizophrenia, and 18 – for BD. Protein set in schizophrenia was mostly associated with immune response, cell communication, cell growth and maintenance, protein metabolism and regulation of nucleic acid metabolism. Protein set in BD was mostly associated with immune response, regulating transport processes across cell membrane and cell communication, development of neurons and oligodendrocytes and cell growth. Concentrations of ankyrin repeat domain-containing protein 12 (ANKRD12) and cadherin 5 in serum samples were determined by ELISA. Significant difference between three groups was revealed in ANKRD12 concentration (p = 0.02), with maximum elevation of ANKRD12 concentration (median level) in schizophrenia followed by BD. Cadherin 5 concentration differed significantly (p = 0.035) between schizophrenic patients with prevailing positive symptoms (4.78 [2.71, 7.12] ng/ml) and those with prevailing negative symptoms (1.86 [0.001, 4.11] ng/ml). Our results are presumably useful for discovering the new pathways involved in endogenous psychotic disorders.

29 December 2009 in Human Psychopharmacology: Clinical and Experimental
Verified
Journal Article
Closed access
PDF file
AHA. F. Y. Al Hadithy
A. F. Y. Al Hadithy
SISvetlana Ivanova
Svetlana Ivanova
PPP. Pechlivanoglou
P. Pechlivanoglou
BWB. Wilffert
B. Wilffert
ASArkadiy Semke
Arkadiy Semke
ALAnton J M Loonen
Anton J M Loonen

14 October 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
IMIrina Mednova
Irina Mednova
ABAnastasiia Sergeevna Boiko
Anastasiia Sergeevna Boiko
EKElena Kornetova
Elena Kornetova
DKDaria A. Kamaeva
Daria A. Kamaeva
ASArkadiy Semke
Arkadiy Semke
SISvetlana Ivanova
Svetlana Ivanova
The adipokines leptin, adiponectin, tumor necrosis factor-alpha (TNF-α), and interleukin 6 (IL-6) might be associated with metabolic syndrome (MetS) in patients with schizophrenia. In the present study, we attempted to confirm the results of previous reports and assessed their MetS-related correlation with body fat composition and biochemical parameters. We measured in 46 patients with schizophrenia and MetS serum levels of adiponectin insulin, leptin, TNF-α and IL-6 and compared these levels to those of patients with schizophrenia without MetS. The MetS patients had significantly increased leptin levels and leptin/adiponectin ratios, as well as decreased adiponectin levels. Leptin levels correlated with several metabolic parameters, both in patients with and without MetS, including body fat percentage, total fat fold, and body mass index (BMI). Patients without abnormal MetS components had lower levels of leptin and leptin/adiponectin ratios compared with patients who had one or two MetS components. Leptin/adiponectin ratios were higher in patients who had four rather than three MetS components. Multiple regression analysis revealed multiple associations for leptin but only one for adiponectin, TNF-α, and IL-6. Our results support an important pathophysiological role for leptin more than adiponectin in patients with schizophrenia with MetS.

25 November 2022 in Life
Verified
Journal Article
Open access
PDF file
IMIrina Mednova
Irina Mednova
ABAnastasiia Sergeevna Boiko
Anastasiia Sergeevna Boiko
EKElena Kornetova
Elena Kornetova
ASArkadiy Semke
Arkadiy Semke
NBNikolay A. Bokhan
Nikolay A. Bokhan
SISvetlana Ivanova
Svetlana Ivanova
Immune activation plays a major role in the pathogenesis of schizophrenia, as confirmed by many studies, systematic reviews, and meta-analyses. The important role of neuroinflammation in the formation of the relation between impaired neurobiological processes and schizophrenia psychopathology is being actively discussed. We quantified serum concentrations of 22 cytokines in 236 patients with schizophrenia and 103 mentally and somatically healthy individuals by a multiplex assay. We found higher TGF-α (p = 0.014), IFN-γ (p = 0.036), IL-5 (p < 0.001), IL-6 (p = 0.047), IL-8 (p = 0.005), IL-10 (p <0.001), IL-15 (p = 0.007), IL-1RA (p = 0.007), and TNF-α (p < 0.001) levels in patients with schizophrenia than in healthy individuals. Subgroup analysis revealed a much greater number of statistically significant differences in cytokine levels among females than among males. Patients with a continuous course of schizophrenia showed statistically significantly higher levels of IL-12p70 (p = 0.019), IL-1α (p = 0.046), and IL-1β (p = 0.035) compared with patients with an episodic course. Most cytokines were positively correlated with positive, general, and total PANSS scores. In patients with a duration of schizophrenia of 10 years or more, the level of IL-10 was higher than that in patients with a disease duration of 5 years or less (p = 0.042). Thus, an imbalance in cytokines was revealed in patients with schizophrenia, depending on sex and clinical characteristics of the disease.